Pathogenicity of catalytic antibodies: Catalytic activity of Bence Jones proteins from myeloma patients with renal impairment can elicit cytotoxic effects

Biological Chemistry

Volumn 387, Issue 5, 2006, Pages 543-548

  Matsuura, Kinji ^a,d   Ohara, Kyoko ^a,d   Munakata, Hiroshi ^b   Hifumi, Emi ^c,d   Uda, Taizo ^c,d  

^a Hanada Clinic and Laboratory   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c PREFECTURAL UNIVERSITY OF HIROSHIMA   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Bence Jones protein; Catalytic antibody; Cytotoxicity; LLC PK1; Multiple myeloma; Renal impairment

Indexed keywords

BENCE JONES PROTEIN; CATALYTIC ANTIBODY; CHROMOGENIC SUBSTRATE; DYFLOS;

ANIMAL CELL; ARTICLE; CANCER PATIENT; CATALYSIS; CELL STRAIN; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; HUMAN; IMMUNOPATHOGENESIS; KIDNEY DYSFUNCTION; MICROSCOPY; MULTIPLE MYELOMA; NICK END LABELING; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; RISK ASSESSMENT; SWINE; SYMPTOM; URINARY EXCRETION;

ANIMALS; ANTIBODIES, CATALYTIC; BENCE JONES PROTEIN; CATALYSIS; CELL SURVIVAL; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENT ANTIBODY TECHNIQUE; FLUORIDES; HUMANS; IN SITU NICK-END LABELING; KIDNEY DISEASES; KINETICS; LLC-PK1 CELLS; MICROSCOPY, PHASE-CONTRAST; MULTIPLE MYELOMA; PHOSPHATES; SWINE;

EID: 33746064821     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2006.070     Document Type: Article

References (36)

1. Buxbaum, J. (1992). Mechanisms of disease, monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol. Oncol. Clin. North Am. 6, 323-346.
2. Dammacco, F. and Waldenstrom, J. (1968). Serum and urine light chain levels in benign monoclonal gammopathies, multiple myeloma and Waldenstrom's macroglobulinaemia. Clin. Exp. Immunol. 3, 911-921.
3. DeFronzo, R.A., Cooke, C.R., Wright, J.R., and Humphrey, R.L. (1978). Renal function in patients with multiple myeloma. Medicine 57, 151-166.
4. Erhan, S. and Greller, L.D. (1974). Do immunoglobulins have proteolytic activity? Nature 251, 353-355.
5. Fang, L.S. (1985). Light-chain nephropathy. Kidney Int. 27, 582-592.
6. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S.A. (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119, 493-501.
7. Hatiuchi, K., Hifumi, H., Mitsuda, Y., and Uda, T. (2003). Endopeptidase character of monoclonal antibody i41-7 subunits. Immunol. Lett. 86, 249-257.
8. Hifumi, E., Okamoto, Y., and Uda, T. (2000). How and why 41S-2 antibody subunits acquire the ability to catalyze decomposition of the conserved sequence of gp41 of HIV-1. Appl. Biochem. Biotechnol. 83, 209-219.
9. Hifumi, E., Kondo, H., Mutsuda, Y., and Uda, T. (2003). Catalytic features of monoclonal antibody i41SL1-2 subunits. Biotechnol. Bioeng. 84, 485-493.
10. Kyle, R.A. and Gartz, M.A. (1995). Primary systemic amyloidosis, clinical and laboratory features in 474 cases. Semin. Hematol. 32, 45-59.
11. Li, L., Paul, S., Tyutyulkova, S., Kazatchkine, M.D., and Kaveri, S. (1995). Catalytic activity of anti-thyroglobulin antibodies. J. Immunol. 154, 3328-3332.
12. Matsuura, K. and Sinohara, H. (1996). Catalytic cleavage of vasopressin by human Bence Jones proteins at the arginyl-glycinamide bond. Biol. Chem. 377, 587-589.
13. Matsuura, K., Yamamoto, K., and Sinohara, H. (1994). Amidase activity of human Bence Jones proteins. Biochem. Biophys. Res. Commun. 204, 57-62.
14. Matsuura, K., Ikoma, S., Yoshida, K., and Sinohara, H. (1998). DNA-hydrolyzing activity of Bence Jones proteins. Biochem. Biophys. Res. Commun. 243, 719-721.
15. Matsuura, K., Ikoma, S., Watanabe, M., Togawa, A., and Sinohara, H. (1999). Some Bence-Jones proteins enter cultured renal tubular cells, reach nuclei and induce cell death. Immunology 98, 584-589.
16. Mitsuda, Y., Hifumi, E., and Uda, T. (2004). Catalytic antibody light chain capable of cleaving a chemokine receptor CCR-5 peptide with a high reaction rate constant. Biotechnol. Bioeng. 86, 217-225.
17. Mori, C., Nakamura, N., Okamoto, Y., Osawa, M., and Shiota, K. (1994). Cytochemical identification of programmed cell death in the fusing fetal mouse palate by specific labelling of DNA fragmentation. Anat. Embryol. 190, 21-28.
18. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival, application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63.
19. Pascali, E. and Pezzoli, A. (1988). The clinical spectrum of pure Bence Jones proteinuria. A study of 66 patients. Cancer 62, 2408-2415.
20. Paul, S. (1996). Natural catalytic antibodies. Mol. Biotechnol. 3, 197-207.
21. Paul, S. (1998). Antibody catalysis. In: Contemporary Immunology, Autoimmune Diseases, S. Paul, ed. (Totowa, NJ, USA: Humana Press), pp. 221-234.
22. Paul, S., Volle, D.J., Beach, C.M., Johnson, D.R., Powell, M.J., and Massey, R.J. (1989). Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science 244, 1158-1162.
23. Paul, S., Li, L., Kalaga, R., Wilkins-Stevens, P., Stevens, F.J., and Solomon, A. (1995). Natural catalytic antibodies, peptide-hydrolyzing activities of Bence Jones proteins and VL fragment. J. Biol. Chem. 270, 15257-15261.
24. Paul, S., Kalaga, R.S., Gololobov, G., and Brenneman, D. (2000). Natural catalytic immunity is not restricted to autoantigenic substrates, identification of a human immunodeficiency virus gp 120-cleaving antibody light chain. Appl. Biochem. Biotechnol. 83, 71-82; 145-153.
25. Preud'homme, J.L., Aucouturier, P., Touchard, G., Striker, L., Khamlichi. A.A., Rocca, A., et al. (1994). Monoclonal immunoglobulin deposition (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney Int. 46, 965-972.
26. Sanders, P.W. (1994). Pathogenesis and treatment of myeloma kidney. J. Lab. Clin. Med. 124, 484-488.
27. Schneider, P. and Tschopp, J. (2000). Apoptosis induced by death receptors. Pharm. Acta Helv. 74, 281-286.
28. Selby, P. and Gore, M. (1995). Myeloma and other plasma cell malignancies. In: Oxford Textbook of Oncology, Vol. 1, M. Peckham, H. Pinego and U. Veronesi, eds. (Oxford, UK: Oxford University Press), pp. 1852-1878.
29. Shuster, A.M., Gololobov, G.V., Kvashuk, O.A., Bogomolova, A.E., Smirnov, I.V., and Gabibov, A.G. (1992). DNA hydrolyzing autoantibodies. Science 256, 665-667.
30. Sinohara, H. and Matsuura, K. (1998). Is catalytic activity of Bence Jones proteins an autoimmune effector mechanism in multiple myeloma? In: Contemporary Immunology, Autoimmune Diseases, S. Paul, ed. (Totowa, NJ, USA: Humana Press), pp. 235-247.
31. Sinohara, H. and Matsuura, K (2000). Catalytic activities and functional effects of Bence Jones proteins. Chem. Immunol. 77, 89-101.
32. Solomon, A., Weiss, D.T., and Kattine, A.A. (1991). Nephrotoxic potential of Bence Jones proteins. N. Engl. J. Med. 324, 1845-1851.
33. Thiagarajan, P., Dannenbring, R., Matsuura, K., Tramontano, A., Gololobov, G., and Paul, S. (2000). Monoclonal antibody light chain with prothrombinase activity. Biochemistry 39, 6459-6465.
34. Wallach, D., Varfolomeev, E.E., Malinin, N.L., Goltsev, Y.V., Kovalenko, A.V., and Boldin, M.P. (1999). Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 17, 331-367.
35. Yokota, N., Yamamoto, Y., Kitamura, K., Kuroki, N., Hisanaga, S., Fujimoto, S., Eto, T., and Tanaka, K. (1991). Renal tubular lesions induced by human Bence Jones protein in the rat, N-acetyl-β-D-glucosaminidase as a sensitive marker. Int. J. Exp. Pathol. 72, 255-262.
36. Yonehara, S., Ishii, A., and Yonehara, M. (1989). A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169, 1747-1756.